NCT05717920View on ClinicalTrials.gov

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

November 21, 2023

Study Completion Date

November 21, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

ADX-629 (Open-label)

ADX-629 (250 mg) administered twice daily for 90 days

Trial Locations (1)

43209

Bexley Dermatology Research, Bexley

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY